Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2019, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.
Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 7, 3, 17 and 5 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 4, 1 and 1 molecules, respectively.
Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenzavirus B Infections - Overview
Influenzavirus B Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenzavirus B Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenzavirus B Infections - Companies Involved in Therapeutics Development
AbbVie Inc
Abhelix LLC
Adimmune Corp
Allergy Therapeutics Plc
Ansun Biopharma Inc
Aphios Corp
AstraZeneca Plc
AusBio Ltd
Biotron Ltd
BlueWillow Biologics Inc
Cidara Therapeutics Inc
Cocrystal Pharma Inc
ContraFect Corp
Daiichi Sankyo Co Ltd
e-Therapeutics Plc
Evotec SE
Evrys Bio
Fujifilm Toyama Chemical Co Ltd
GC Pharma
Imutex Ltd
Inovio Pharmaceuticals Inc
iQur Ltd
Johnson & Johnson
Medicago Inc
Novavax Inc
Osivax SAS
Park Active Molecules
Romark Laboratories LC
Sanofi Pasteur SA
Sciogen Inc
Seqirus Ltd
Serum Institute of India Ltd
Shanghai Institute of Biological Products Co Ltd
Shionogi & Co Ltd
Sinovac Biotech Ltd
Therapeutic Systems Research Laboratories Inc
UMN Pharma Inc
Vacthera BioTech GmbH
Vaxart Inc
Ventaleon GmbH
Viramatix Sdn Bhd
Wuhan Institute of Biological Products Co Ltd
Influenzavirus B Infections - Drug Profiles
Afluria Quadrivalent - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-0205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baloxavir marboxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-12G6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAS-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETS-5200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
favipiravir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Flu-v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluad (Quadrivalent) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fludase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluzone QIV HD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3106A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Influenzavirus B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Hemagglutinin for Influenza Virus A and B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza (quadrivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A + B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1+A/H3N2+B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
laninamivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDG-2271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Influenza B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Influenza B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block M2 Proton Channel for Influenzavirus A and B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Sirtuin for Influenza - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PA for Influenzavirus A and B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMTX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VR-736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTH-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXABYW-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zanamivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenzavirus B Infections - Dormant Projects
Influenzavirus B Infections - Discontinued Products
Influenzavirus B Infections - Product Development Milestones
Featured News & Press Releases
Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
Oct 03, 2019: Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
Aug 29, 2019: Shionogi announces XOFLUZA tablets 20mg for the treatment of Influenza Types A and B in patients 12 years of age and older approved in Taiwan.
Aug 21, 2019: Cidara Therapeutics to present data from its Cloudbreak antiviral program at the Options X for the Control of Influenza conference
Jun 05, 2019: Cidara Therapeutics to present new data on CB-012 at ASM Microbe 2019
Apr 15, 2019: Cidara Therapeutics selects first clinical development candidate from its Cloudbreak Influenza (Antiviral) Program
Jan 27, 2019: Flu viruses resistant to new drug Xofluza uncovered in Japan
Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults
Oct 24, 2018: Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Sep 27, 2018: Shionogi to present data on Baloxavir Marboxil at IDWeek 2018
Sep 06, 2018: Baloxavir Marboxil phase II and III studies for the treatment of Influenza published in the New England Journal of Medicine
Jul 30, 2018: Sanofi ships first flu vaccines for 2018-2019 season
Jul 16, 2018: Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
Jul 02, 2018: Shionogi Filed for the New Drug Application of Baloxavir Marboxil in Taiwan for the Treatment of Influenza
Jun 26, 2018: Roche’s influenza drug secures FDA priority review status
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Influenzavirus B Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Universities/Institutes, H2 2019
Table 6: Products under Development by Companies, H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 10: Products under Development by Universities/Institutes, H2 2019
Table 11: Number of Products by Stage and Target, H2 2019
Table 12: Number of Products by Stage and Mechanism of Action, H2 2019
Table 13: Number of Products by Stage and Route of Administration, H2 2019
Table 14: Number of Products by Stage and Molecule Type, H2 2019
Table 15: Influenzavirus B Infections - Pipeline by AbbVie Inc, H2 2019
Table 16: Influenzavirus B Infections - Pipeline by Abhelix LLC, H2 2019
Table 17: Influenzavirus B Infections - Pipeline by Adimmune Corp, H2 2019
Table 18: Influenzavirus B Infections - Pipeline by Allergy Therapeutics Plc, H2 2019
Table 19: Influenzavirus B Infections - Pipeline by Ansun Biopharma Inc, H2 2019
Table 20: Influenzavirus B Infections - Pipeline by Aphios Corp, H2 2019
Table 21: Influenzavirus B Infections - Pipeline by AstraZeneca Plc, H2 2019
Table 22: Influenzavirus B Infections - Pipeline by AusBio Ltd, H2 2019
Table 23: Influenzavirus B Infections - Pipeline by Biotron Ltd, H2 2019
Table 24: Influenzavirus B Infections - Pipeline by BlueWillow Biologics Inc, H2 2019
Table 25: Influenzavirus B Infections - Pipeline by Cidara Therapeutics Inc, H2 2019
Table 26: Influenzavirus B Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
Table 27: Influenzavirus B Infections - Pipeline by ContraFect Corp, H2 2019
Table 28: Influenzavirus B Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Table 29: Influenzavirus B Infections - Pipeline by e-Therapeutics Plc, H2 2019
Table 30: Influenzavirus B Infections - Pipeline by Evotec SE, H2 2019
Table 31: Influenzavirus B Infections - Pipeline by Evrys Bio, H2 2019
Table 32: Influenzavirus B Infections - Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019
Table 33: Influenzavirus B Infections - Pipeline by GC Pharma, H2 2019
Table 34: Influenzavirus B Infections - Pipeline by Imutex Ltd, H2 2019
Table 35: Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Table 36: Influenzavirus B Infections - Pipeline by iQur Ltd, H2 2019
Table 37: Influenzavirus B Infections - Pipeline by Johnson & Johnson, H2 2019
Table 38: Influenzavirus B Infections - Pipeline by Medicago Inc, H2 2019
Table 39: Influenzavirus B Infections - Pipeline by Novavax Inc, H2 2019
Table 40: Influenzavirus B Infections - Pipeline by Osivax SAS, H2 2019
Table 41: Influenzavirus B Infections - Pipeline by Park Active Molecules, H2 2019
Table 42: Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H2 2019
Table 43: Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H2 2019
Table 44: Influenzavirus B Infections - Pipeline by Sciogen Inc, H2 2019
Table 45: Influenzavirus B Infections - Pipeline by Seqirus Ltd, H2 2019
Table 46: Influenzavirus B Infections - Pipeline by Serum Institute of India Ltd, H2 2019
Table 47: Influenzavirus B Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019
Table 48: Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H2 2019
Table 49: Influenzavirus B Infections - Pipeline by Sinovac Biotech Ltd, H2 2019
Table 50: Influenzavirus B Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2019
Table 51: Influenzavirus B Infections - Pipeline by UMN Pharma Inc, H2 2019
Table 52: Influenzavirus B Infections - Pipeline by Vacthera BioTech GmbH, H2 2019
Table 53: Influenzavirus B Infections - Pipeline by Vaxart Inc, H2 2019
Table 54: Influenzavirus B Infections - Pipeline by Ventaleon GmbH, H2 2019
Table 55: Influenzavirus B Infections - Pipeline by Viramatix Sdn Bhd, H2 2019
Table 56: Influenzavirus B Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2019
Table 57: Influenzavirus B Infections - Dormant Projects, H2 2019
Table 58: Influenzavirus B Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 59: Influenzavirus B Infections - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Influenzavirus B Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
